Endocrinol Metab > Volume 30(3); 2015 > Article
Yoo, Chin, Lee, and Koh: Factors Associated with Glycemic Variability in Patients with Type 2 Diabetes: Focus on Oral Hypoglycemic Agents and Cardiovascular Risk Factors



The role of glycemic variability (GV) in development of cardiovascular diseases remains controversial, and factors that determine glucose fluctuation in patients with diabetes are unknown. We investigated relationships between GV indices, kinds of oral hypoglycemic agents (OHAs), and cardiovascular risk factors in patients with type 2 diabetes mellitus (T2DM).


We analyzed 209 patients with T2DM. The GV index (standard deviation [SD] and mean absolute glucose change [MAG]) were calculated from 7-point self-monitoring of blood glucose profiles. The patients were classified into four groups according to whether they take OHAs known as GV-lowering (A) and GV-increasing (B): 1 (A only), 2 (neither), 3 (both A and B), and 4 (B only). The 10-year risk for atherosclerotic cardiovascular disease (ASCVD) was calculated using the Pooled Cohort Equations.


GV indices were significantly higher in patients taking sulfonylureas (SUs), but lower in those taking dipeptidyl peptidase-4 inhibitors. In hierarchical regression analysis, the use of SUs remained independent correlates of the SD (β=0.209, P=0.009) and MAG (β=0.214, P=0.011). In four OHA groups, GV indices increased progressively from group 1 to group 4. However, these did not differ according to quartiles of 10-year ASCVD risk.


GV indices correlated significantly with the use of OHAs, particularly SU, and differed significantly according to combination of OHAs. However, cardiovascular risk factors and 10-year ASCVD risk were not related to GV indices. These findings suggest that GV is largely determined by properties of OHAs and not to cardiovascular complications in patients with T2DM.


It is assumed that hyperglycemia contributes to chronic complications of diabetes by inducing oxidative stress [1]. Previous studies have shown that intensive glycemic control reduces the rate of microvascular complications in type 1 and type 2 diabetes [2,3]. Glycated hemoglobin (HbA1c) is a marker of chronic hyperglycemia and is a strong predictor of complications of diabetes [4]. However, patients with similar HbA1c values can have markedly different glucose profiles and complications of diabetes. Numerous in vitro studies have shown that not only chronic hyperglycemia but also acute glycemic excursions induce oxidative stress and contribute to endothelial dysfunction [5,6]. Such findings have raised concerns about the effects of glucose fluctuation on complications of diabetes. Glycemic variability (GV) refers to the swing in blood glucose concentration from peaks to nadirs. Although there are several indices, there is no "gold standard" for quantifying GV. The standard deviation (SD) is the most commonly used method to assess GV. The mean absolute glucose change (MAG) is the mean absolute change in glucose concentration per unit of time [7] and shows a stronger association with intensive care unit mortality than does SD.
Factors that might contribute to GV include decreased endogenous insulin secretion, deficiency in the relevant suppression of glucagon, and use of hypoglycemic agents. There are many oral hypoglycemic agents (OHAs) used in the treatment of diabetes, but each has different effects on GV. Small intervention studies have reported that the OHAs affecting predominantly postprandial hyperglycemia including α-glucosidase inhibitors (AGIs) and dipeptidyl peptidase-4 inhibitors (DPP4is) decrease GV [8,9]. Sulfonylureas (SUs) are effective in lowering both fasting and postprandial glucose levels. The use of SUs is positively and independently associated with GV measured as the mean amplitude of glycemic excursion (MAGE) [10].
There is controversy about the role of GV in the development of cardiovascular diseases. In addition, there have been few studies to identify the factors that affect GV in patients with type 2 diabetes. Postprandial hyperglycemia, a component of GV, has been proposed as an independent risk factor for cardiovascular disease [11,12]. In the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) study [13], the use of acarbose, an AGI-targeting postprandial hyperglycemic agent, prevented the development of cardiovascular disease in subjects with impaired glucose. However, the primary outcome of that study was the development of diabetes, not cardiovascular disease. There were also only small differences in postprandial glucose levels. In 2010, the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial [14] showed negative results in this regard, in which the use of nateglinide, a short-acting SU analog, did not reduce cardiovascular outcomes in subjects with impaired glucose tolerance.
The aims of the study were to assess whether OHAs and cardiovascular risk factors were associated with indices of GV and to identify other factors that contributed to GV in patients with type 2 diabetes.



The Division of Endocrinology and Metabolism, Jeju National University Hospital, had been providing free-of-charge glucometer and test strips for outpatients with diabetes. The patients were encouraged to record a 7-point self-monitoring of blood glucose (SMBG) profile (preprandial/2-hour postprandial at each meal and at bedtime) once monthly. We reviewed the medical records of 209 patients who visited Jeju National University Hospital from August 2009 through October 2011 who met the following criteria: (1) 20 to 80 years of age; (2) patients with type 2 diabetes who did not use insulin; (3) patients who had no history of cardiovascular disease; (4) patients who performed a 7-point SMBG once a month for 4 consecutive months; (5) patients who did not change the type or dose of OHAs within the 2 months before the 4 consecutive months; and (6) patients who underwent HbA1c testing in month 4 of blood glucose monitoring. Patients were excluded if they were taking steroids or hormones that can influence blood glucose level or if they changed the dose or type of OHAs during the 4 consecutive months of recording the 7-point SMBG. This study was approved by the Institutional Review Board of Jeju National University Hospital, which waived the need for informed consent because of the retrospective nature of this study.


We chose SD and MAG as the indices of GV. The glycemic indices were calculated using the 7-point SMBG data checked once monthly for 4 consecutive months (Fig. 1). The SD was calculated as the arithmetic SD, and the MAG was the mean of the absolute change in glucose concentration per hour [7]. We calculated the means of the 4-monthly SD and MAG for each subject and used the means for data analysis. HbA1c levels measured in month 4 were retrieved from medical records (Fig. 1). The treatment regimen of diabetes, use of statin, duration of diabetes in years, body mass index, waist circumference (WC), blood pressures, fasting C-peptide and high-sensitivity C-reactive protein (hsCRP) concentrations, estimated glomerular filtration rate, urine albumin:creatinine ratio (UACR), ankle-brachial pressure index (ABI), and concentrations of uric acid, total cholesterol, triglyceride (TG), high density lipoprotein cholesterol (HDL-C), and low density lipoprotein cholesterol (LDL-C) were assessed. The frequency of hypoglycemia was defined as the number of blood glucose measurements ≤3.9 mmol/L on the 7-point SMBG recorded once a month for the 4 consecutive months. The 10-year risk for atherosclerotic cardiovascular disease (ASCVD) was calculated using the Pooled Cohort Equations [15].
We classified each patient's treatment regimen of diabetes into four categories according to the ability of OHAs to affect GV. Because DPP4is, glucagon-like peptide 1 (GLP-1) receptor agonists, AGIs, and glinides improve GV [8,9,16,17], we classified these OHAs as GV-lowering medication. SUs were classified as GV-increasing medications [10]. There have been no studies conducted to determine the effects of metformin and thiazolidinedione (TZD) on GV. In this study, no patients were treated with GLP-1 receptor agonists or glinides. Therefore, only the uses of DPP4is, AGIs, and SUs were considered for the OHA grouping. Group 1 included those patients using only GV-lowering medications (DPP4is/AGIs). Group 2 included patients using medications that did not influence GV (OHAs other than DPP4is, AGIs and SUs). Group 3 included those using both GV-decreasing and -increasing medications (DPP4is/AGIs and SUs). Group 4 included those using only GV-increasing medication (SUs).

Statistical analysis

All data are presented as the mean±standard error, unless mentioned otherwise. Pearson correlations were performed to evaluate the simple relationships between the indices of GV and clinical and laboratory variables. Student t test was used to analyze the differences in GV indices according to the use of individual OHAs. The use of individual OHA was defined as whether or not taking medication regardless of combination therapy. Kruskal-Wallis test and Mann-Whitney test were performed to compare the median value of GV indices according to types of OHA therapy. Hierarchical regression analysis was performed to assess the stepwise contribution of OHAs and cardiovascular risk factors to the indices of GV. Model 1 included age, sex, and factors that were significantly related to GV indices in the Pearson correlational analyses (HbA1c, duration of diabetes, frequency of hypoglycemia, and C-peptide level). In model 2, the use of individual OHA was introduced. Finally, in model 3, other known cardiovascular risk factors (UACR, WC, and concentrations of LDL-C and HDL-C, TG, hsCRP, and uric acid) were added. The subjects were classified into four groups according to the OHAs and 10-year risk of ASCVD. Analysis of variance (ANOVA) with a linear trend test was used to compare the mean values of SD and MAG between the four groups. The level of significance was defined as P<0.05. Statistical analyses were performed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA).


Patients' characteristics

In total, 209 patients with type 2 diabetes who were not receiving insulin therapy were included in this study. Most were obese and middle-aged men. Their diabetes was relatively well controlled in terms of blood glucose level, despite the considerable duration of diabetes. Most patients had a high cardiovascular risk according to the 10-year ASCVD risk profile. Many were being treated with metformin or SUs, and a few were treated with DPP4is, TZDs, or AGIs (Table 1).

Univariate and multivariate analyses of the indices of glycemic variability

In the Pearson correlational analysis, HbA1c, duration of diabetes, and C-peptide level correlated with both the SD and MAG, and the frequency of hypoglycemia correlated significantly with SD. Known cardiovascular risk factors such as obesity, lipid profile, uric acid level, albuminuria, and ABI did not correlate significantly with the SD or MAG (Table 2).
We investigated the differences of GV indices between user and non-user of individual OHAs using Student t tests. Both the SD and MAG were significantly higher in patients taking SUs, but lower in those taking DPP4is. However, the indices of GV were not different with the use of AGI, metformin, or TZD (Fig. 2). In this study, about 70% of patients took more than two OHAs. In patients with dual-therapy, median value of SD and MAG was significantly higher in patient with taking MET plus SU (SD, 2.547 mmol/L [interquartile range (IQR), 2.140 to 3.158]; MAG, 1.301 mmol/L/hr [IQR, 1.098 to 1.660]) than MET plus DPP4i (SD, 1.658 mmol/L [IQR, 1.352 to 2.267]; MAG, 0.824 mmol/L/hr [IQR, 0.693 to 1.168]; P<0.001, respectively) (Table 3).
Hierarchical regression analysis was used to adjust for HbA1c, other covariates, OHAs, and cardiovascular risk factors. HbA1c, frequency of hypoglycemia, and C-peptide level contributed significantly to both the SD and MAG after adjusting for age and sex in model 1. The addition of OHAs increased the adjusted R2 of model 2 by 5.7% and 7.9% for the SD and MAG, respectively, compared with model 1. In model 2, the use of SUs was a positive predictor and AGIs a negative predictor of the SD and MAG. HbA1c level and the frequency of hypoglycemia significantly contributed to the indices of GV after adjusting for OHAs, but C-peptide level did not contribute. In model 3, added cardiovascular risk factors (albuminuria, waist circumference, and concentrations of LDL-C and HDL-C, triglyceride, hsCRP, and uric acid) did not contribute significantly to the two GV indices. Rather, the adjusted R2 values of model 3 decreased by 0.7% and 1.6% for the SD and MAG, respectively, compared with model 2. The HbA1c level, frequency of hypoglycemia, and the use of SUs remained significant predictors of the SD and MAG in model 3 (Table 4).

Comparison of indices of glycemic variability between the four groups according to OHA usage and 10-year ASCVD risk

We comprehensively analyzed the effects of OHAs and cardiovascular risk factors on GV. The patients were divided into four groups according to the ability of the OHAs to affect GV (Supplemental Table S1). They were also divided into four quartiles of the 10-year ASCVD risk. The SD and MAG differed significantly between four groups (P ANOVA <0.001) and increased progressively from group 1 to group 4 (P for trend <0.001) (Fig. 3). By contrast, there was no significant difference in the SD and MAG between quartiles of 10-year ASCVD risk. The two indices also did not tend to change with increasing quartiles of 10-year ASCVD risk (Fig. 4).


In this study, we investigated the association between GV and cardiovascular risk factors, and we identified the independent contributors to GV. The GV indices were related to the type of OHAs rather than to cardiovascular risk factors. The use of SUs was independently related, but cardiovascular risk factors were not related to GV. Our findings are consistent with previous studies showing that GV measured as MAGE was not related to risk factors for cardiovascular disease [18] and that the type of OHAs were associated with GV [10].
Of the OHAs included in our analysis, only the use of SUs was finally related to the indices of GV in the multivariate analysis. The use of SUs remained a significant predictor of GV indices even after adjusting for hypoglycemia in the multivariate analysis. Some previous studies have also reported that the use of SUs increases GV in patients with type 2 diabetes [19,20]. However, β-cell dysfunction might be a confounding factor in our multivariate analysis because SUs had been used primarily by patients with diabetes who impaired insulin secretion. We included basal C-peptide level in the multivariate analysis to adjust for insulin secretory function. However, the basal C-peptide level did not accurately reflect β-cell function in these patients with type 2 diabetes [21]. Therefore, the poststimulation C-peptide level should be used in future studies to confirm the contribution of β-cell function to GV.
Users of DPP4is had significantly lower GV indices than nonusers, as shown by the t test. The use of AGIs remained a significant predictor of SD and MAG in model 2 of the stepwise multiple regression. However, in model 3 of the stepwise multivariate analysis, DPP4is and AGIs were no longer predictors of GV. Many researchers have reported that DPP4is or AGIs significantly improve GV independently of the HbA1c level in patients with type 2 diabetes [8,9]. Fig. 3 shows that the patients treated with either DPP4is or AGIs had the lowest indices of GV and that group 3 (users of SUs and either DPP4is or AGIs) had lower GV indices than group 4 (only SUs). This finding suggests that the negative effect of SUs on GV may be offset by adding DPP4is or AGIs. Therefore, the results of the multivariate analysis cannot exclude the diminishing effect of DPP4is and AGIs on GV. A larger study will help to clarify the effects of DPP4is and AGIs.
The Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus (HEART2D) trial was a randomized controlled trial that compared the effects of prandial versus basal insulin therapy on the risk for subsequent cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes [22]. This trial showed significant differences in postprandial glucose levels between the two treatment groups. GV measured as MAG was significantly lower in the group treated with prandial insulin than basal insulin [23], but there were no differences in cardiovascular outcomes between the two treatment groups. Our finding of no differences in GV between quartiles of the 10-year ASCVD risk is consistent with this result of the HEART2D trial.
Our study had some limitations. First, we used the SMBG system and not a continuous glucose monitoring system (CGMS) to assess GV. The CGMS is preferable for assessing GV because SMBG can miss certain peaks or nadirs in glucose values. The MAGE probably remains the most comprehensive index for assessing GV, and its measurement generally requires CGMS [24]. However, it is difficult to perform CGMS in daily practice because of discomfort, cost, and the need for calibration. Therefore, many indices using SMBG data have been developed. Among them, SD and MAG are easy and widely available indices that can be calculated using SMBG data, and they have been shown to correlate strongly with the different indices of GV using CGMS data [25,26]. Second, the cross-sectional design of this study made it difficult to assess the occurrence of cardiovascular outcomes. Thus, we used individual cardiovascular risk factors and the estimated 10-year ASCVD risk. We calculated the 10-year ASCVD risk using the Pooled Cohort Equations [15], which are applicable to patients with diabetes, unlike the Framingham Risk Score [27]. Further longitudinal study is needed to investigate the effects of GV on diabetic complications. Third, we did not evaluate the effect of insulin use on GV. We excluded insulin-treated patients to preclude any with type 1 diabetes. Therefore, our results do not apply to patients with diabetes treated with insulin.
In summary, the indices of GV were significantly related to the uses of OHAs in patients with type 2 diabetes. In particular, the use of SUs positively predicted the indices after adjusting for HbA1c level, hypoglycemia, and other covariates. Cardiovascular risk factors were not associated with the GV indices. The GV indices differed significantly between different combinations of OHAs. However, the 10-year ASCVD risk was not related to the GV indices. These findings suggest that GV is determined largely by the properties of OHAs and not by cardiovascular complications in patients with type 2 diabetes. We believe that further prospective studies will confirm our findings.


This work was supported by a research grant from Jeju National University in 2012. The biospecimens and data used in this study were provided by the Biobank of Jeju University Hospital, a member of Korea Biobank Network.


CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.

Supplementary Material

Supplemental Table S1

Clinical Characteristics of Four Groups according to Oral Hypoglycemic Agent Usage

Values are expressed as number (%) or mean¡¾standard error.

AGI, α-glucosidase inhibitor; DPP4i, dipeptidyl peptidase-4 inhibitor; SU, sulfonylurea; HbA1c, glycated hemoglobin; MET, metformin; TZD, thiazolidinedione.

Characteristic Group 1 Group 2 Group 3 Group 4
Use of AGI or DPP4i Yes No Yes No
Use of SU No No Yes Yes
Number 27 (11.4) 59 (25.0) 12 (5.1) 111 (47.0)
Age, yr 61.48±1.2 56.12±1.33 60.75±2.68 58.5±0.76
Male sex 16 (59.3) 39 (66.1) 6 (50.0) 146 (69.9)
Duration of diabetes, yr 7.75±0.96 3.66±0.66 10.31±1.64 9.67±0.66
Body mass index, kg/m2 25.24±0.61 25.97±0.37 25.83±1.34 26.37±0.31
HbA1c, % 6.81±0.13 6.8±0.12 7.2±0.19 7.18±0.08
Use of MET or TZD 27 (100) 43 (73) 9 (75) 109 (98)


1. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-820.
2. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
4. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412.
5. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 2003;52:2795-2804.
6. Horvath EM, Benko R, Kiss L, Muranyi M, Pek T, Fekete K, et al. Rapid 'glycaemic swings' induce nitrosative stress, activate poly(ADP-ribose) polymerase and impair endothelial function in a rat model of diabetes mellitus. Diabetologia 2009;52:952-961.
7. Hermanides J, Vriesendorp TM, Bosman RJ, Zandstra DF, Hoekstra JB, Devries JH. Glucose variability is associated with intensive care unit mortality. Crit Care Med 2010;38:838-842.
8. Wang JS, Lin SD, Lee WJ, Su SL, Lee IT, Tu ST, et al. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison. Clin Ther 2011;33:1932-1942.
9. Guerci B, Monnier L, Serusclat P, Petit C, Valensi P, Huet D, et al. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study. Diabetes Metab 2012;38:359-366.
10. Kohnert KD, Augstein P, Zander E, Heinke P, Peterson K, Freyse EJ, et al. Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Diabetes Care 2009;32:1058-1062.
11. Ceriello A. Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 2005;54:1-7.
12. DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397-405.
13. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486-494.
14. NAVIGATOR Study Group. Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B, et al. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1463-1476.
15. Andrus B, Lacaille D. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. J Am Coll Cardiol 2014;63(25 Pt A):2886
16. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-569.
17. Yamazaki M, Hasegawa G, Majima S, Mitsuhashi K, Fukuda T, Iwase H, et al. Effect of repaglinide versus glimepiride on daily blood glucose variability and changes in blood inflammatory and oxidative stress markers. Diabetol Metab Syndr 2014;6:54
18. Borg R, Kuenen JC, Carstensen B, Zheng H, Nathan DM, Heine RJ, et al. HbA(1)(c) and mean blood glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycaemia or glucose variability in persons with diabetes: the A1C-Derived Average Glucose (ADAG) study. Diabetologia 2011;54:69-72.
19. Jin SM, Kim TH, Bae JC, Hur KY, Lee MS, Lee MK, et al. Clinical factors associated with absolute and relative measures of glycemic variability determined by continuous glucose monitoring: an analysis of 480 subjects. Diabetes Res Clin Pract 2014;104:266-272.
20. Bradescu OM, Ionescu-Tirgoviste C. Correlates of the diurnal plasma glucose variability in non-insulin-treated type 2 diabetic patients. Proc Rom Acad Ser B 2008;1:53-58.
21. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, Battelino T, Haastert B, Ludvigsson J, et al. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008;31:1966-1971.
22. Raz I, Wilson PW, Strojek K, Kowalska I, Bozikov V, Gitt AK, et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009;32:381-386.
23. Siegelaar SE, Kerr L, Jacober SJ, Devries JH. A decrease in glucose variability does not reduce cardiovascular event rates in type 2 diabetic patients after acute myocardial infarction: a reanalysis of the HEART2D study. Diabetes Care 2011;34:855-857.
24. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970;19:644-655.
25. Rodbard D. New and improved methods to characterize glycemic variability using continuous glucose monitoring. Diabetes Technol Ther 2009;11:551-565.
26. Kohnert KD, Heinke P, Fritzsche G, Vogt L, Augstein P, Salzsieder E. Evaluation of the mean absolute glucose change as a measure of glycemic variability using continuous glucose monitoring data. Diabetes Technol Ther 2013;15:448-454.
27. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
Fig. 1

Diagram of schedule for 7-point self-monitoring of blood glucose (SMBG) and glycated hemoglobin (HbA1c) measurements.

Fig. 2

Differences in standard deviation (A) and mean absolute glucose change (B) grouped according to the use of individual oral hypoglycemic agents. SU, sulfonylurea; DPP4i, dipeptidyl peptidase-4 inhibitor; AGI, α-glucosidase inhibitor; MET, metformin; TZD, thiazolidinedione. aP<0.05 by Student t test.

Fig. 3

Differences in standard deviation (A) and mean absolute glucose change (B) according to oral hypoglycemic agent groups. Group 1: dipeptidyl peptidase-4 inhibitor (DPP4i) or α-glucosidase inhibitor (AGI)-use/sulfonylurea (SU)-non-use; group 2: DPP4i or AGI-non-use/SU-non-use; group 3: DPP4i or AGI-use/SU-use; and group 4: DPP4i or AGI-non-use/SU-use. On grouping, the administration of thiazolidinedione and metformin was not considered. ANOVA, analysis of variance.

Fig. 4

Differences in standard deviation (A) and mean absolute glucose change (B) according to quartiles of 10-year atherosclerotic cardiovascular disease (ASCVD) risk. Quartiles of 10-year ASCVD risk: first quartile range ≤7.9%, second quartile range 8% to 13.9%, third quartile range 14% to 23.9%, and fourth quartile range ≥24%. ANOVA, analysis of variance.

Table 1

Patients' Clinical and Laboratory Characteristics

Values are expressed as mean±standard error.

HbA1c, glycated hemoglobin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; hsCRP, high-sensitivity C-reactive protein; eGFR, estimated glomerular filtration rate; UACR, urine albumin: creatinine ratio; ABI, ankle-brachial pressure index; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; MAG, mean absolute glucose change; SU, sulfonylurea; MET, metformin; TZD, thiazolidinedione; DPP4i, dipeptidyl peptidase-4 inhibitor; AGI, α-glucosidase inhibitor; ASCVD, atherosclerotic cardiovascular disease.

Characteristic Value
Number 209
Male sex, % 69.9
Age, yr 58.3±0.6
Body mass index, kg/m2 26.1±0.2
Waist circumference, cm 90.0±0.6
Systolic blood pressure, mm Hg 138.0±1.2
Duration of diabetes, yr 7.8±0.5
C-peptide, nmol/L 0.75±0.02
HbA1c, mmol/mol 53.0±0.6
HbA1c, % 7.0±0.1
AST, IU/L 26.2±0.8
ALT, IU/L 31.4±1.3
hsCRP, mmol/L 14.3±1.9
Uric acid, µmol/L 310.0±5.1
eGFR, mL/min/1.73 m2 72.9±0.8
UACR, mg/g 156.3±26.5
ABI 1.2±0.1
Total cholesterol, mmol/L 4.48±0.06
Triglyceride, mmol/L 1.48±0.06
HDL-C, mmol/L 1.24±0.02
LDL-C, mmol/L 2.73±0.06
Standard deviation 2.23±0.06
MAG, mmol/L/hr 1.17±0.03
Use of SU, % 59.3
Use of MET, % 81.8
Use of TZD, % 8.1
Use of DPP4i, % 12.9
Use of AGI, % 5.7
Frequency of hypoglycemia 0.16±0.04
10-Year ASCVD risk, % 17.1±0.8
Table 2

Pearson's Correlational Analysis of the Relationships between Indices of Glycemic Variability and Cardiovascular Risk Factors

HbA1c, glycated hemoglobin; UACR, urine albumin:creatinine ratio; hsCRP, high-sensitivity C-reactive protein; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; ABI, ankle-brachial pressure index.

aCorrelation coefficient.

Variable Standard deviation Mean absolute glucose change
ra P value ra P value
HbA1c, mmol/mol 0.333 <0.001 0.230 <0.001
Duration of diabetes, yr 0.238 <0.001 0.158 0.025
Frequency of hypoglycemia 0.166 0.016 0.137 0.051
C-peptide, nmol/L 0.161 0.020 0.186 0.008
UACR, mg/g 0.123 0.078 -0.030 0.676
Waist circumference, cm 0.078 0.265 0.102 0.149
Body mass index, kg/m2 0.057 0.410 0.050 0.483
Triglyceride, mmol/L 0.098 0.159 0.126 0.074
hsCRP, mmol/L -0.060 0.392 -0.074 0.291
HDL-C, mmol/L -0.041 0.559 -0.064 0.363
LDL-C, mmol/L -0.077 0.266 -0.027 0.699
Uric acid, µmol/L -0.089 0.201 0.008 0.915
eGFR, mL/min/1.73 m2 0.023 0.737 0.000 0.995
ABI 0.025 0.721 0.031 0.664
Table 3

Differences in Glycemic Variability Indices according to the Regimen of Antidiabetic Agents

Values are expressed as median (interquartile range).

SD, standard deviation; MAG, mean absolute glucose change; MET, metformin; SU, sulfonylurea; DPP4i, dipeptidyl peptidase-4 inhibitor; AGI, α-glucosidase inhibitor; TZD, thiazolidinedione.

aP<0.05 when compared with MET+SU by Mann-Whitney test.

Variable SD, mmol/L MAG, mmol/L/hr
Drug naïve (n=18) 1.775 (1.389-2.023)a 0.920 (0.674-1.119)a
Mono-therapy (n=50)
 MET (n=39) 1.624 (1.452-2.328)a 0.863 (0.669-1.277)a
 SU (n=11) 2.260 (1.925-3.263) 1.122 (0.955-1.833)
Dual-therapy (n=122)
 MET+DPP4i (n=25) 1.658 (1.352-2.267)a 0.824 (0.693-1.168)a
 MET+SU (n=85) 2.547 (2.140-3.158) 1.301 (1.098-1.660)
Triple-therapy (n=19)
 MET+SU+AGI (n=9) 1.621 (1.157-2.886)a 0.726 (0.525-1.368)a
 MET+SU+TZD (n=9) 2.168 (2.037-2.449) 1.307 (1.095-1.588)
Table 4

Hierarchical Multiple Regression Analysis between Indices of Glycemic Variability and Other Variables

R2, adjusted R squared; β, corrected regression coefficient; HbA1c, glycated hemoglobin; SU, sulfonylurea; DPP4i, dipeptidyl peptidase-4 inhibitor; AGI, α-glucosidase inhibitor; MET, metformin; TZD, thiazolidinedione; UACR, urine albumin:creatinine ratio; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein.

aThe use of individual oral hypoglycemic agent was defined as whether or not taking the medication regardless of combination therapy.

Variable Standard deviation Mean absolute glucose change
Model 1
(R2 =0.185)
Model 2
(R2 =0.242)
Model 3
(R2 =0.235)
Model 1
(R2 =0.116)
Model 2
(R2 =0.195)
Model 3
(R2 =0.179)
β P value β P value β P value β P value β P value β P value
Age, yr 0.040 0.540 0.068 0.290 0.057 0.400 0.024 0.731 0.057 0.405 0.060 0.403
Male sex 0.031 0.639 0.004 0.950 0.005 0.946 0.121 0.086 0.083 0.225 0.100 0.181
HbA1c, mmol/mol 0.325 <0.001 0.288 <0.001 0.264 <0.001 0.236 0.001 0.192 0.007 0.190 0.013
Duration of diabetes, yr 0.152 0.024 0.088 0.209 0.107 0.158 0.100 0.161 0.026 0.722 0.072 0.366
Frequency of hypoglycemia 0.233 <0.001 0.189 0.004 0.205 0.002 0.209 0.003 0.162 0.017 0.158 0.024
C-peptide, nmol/L 0.151 0.024 0.087 0.193 0.106 0.174 0.160 0.024 0.093 0.183 0.109 0.183
Use of SUa - - 0.231 0.003 0.209 0.009 - - 0.248 0.002 0.214 0.011
Use of DPP4ia - - -0.096 0.168 -0.114 0.113 - - -0.135 0.066 -0.144 0.059
Use of AGIa - - -0.142 0.024 -0.111 0.095 - - -0.144 0.030 -0.128 0.067
Use of METa - - 0.051 0.417 0.042 0.522 - - 0.071 0.280 0.061 0.376
Use of TZDa - - -0.050 0.443 -0.072 0.296 - - -0.037 0.581 -0.039 0.586
UACR, mg/g - - - - 0.046 0.489 - - - - -0.085 0.229
Waist circumference, cm - - - - 0.074 0.347 - - - - 0.037 0.659
LDL-C, mmol/L - - - - -0.108 0.112 - - - - -0.074 0.295
HDL-C, mmol/L - - - - -0.009 0.903 - - - - 0.024 0.747
Triglyceride, mmol/L - - - - -0.011 0.891 - - - - 0.036 0.651
hsCRP, mmol/L - - - - -0.059 0.380 - - - - -0.083 0.243
Uric acid, µmol/L - - - - -0.059 0.435 - - - - 0.020 0.799
METRICS Graph View
  • 4 Crossref
  • 3 Scopus
  • 946 View
  • 8 Download
Related articles

Editorial Office
101-2503, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-716-2428    Fax: +82-2-714-5103    E-mail: journal@endocrinology.or.kr                

Copyright © 2021 by Korean Endocrine Society. All rights reserved.

Developed in M2PI

Close layer
prev next